Reframing Pharma Supply Chains Through Platform-Based Models

Nearly nine in ten prescriptions filled in the United States are for generic drugs. A significant share of those generics — and the active pharmaceutical ingredients inside them — are manufactured in India. What most Americans don’t consider when they pick up a prescription is how far that medicine has traveled, and how many regulatory checkpoints it passed through to get there. Global pharmaceutical manufacturing has become one of the most complex and consequential supply chain systems in the world.

For companies such as HRV Pharma out of India, the standardized scale of manufacturing has expanded alongside its complexities. In addition to coordinating manufacturing timelines and distribution, regulatory compliance has also become an ongoing operational challenge, which new models are now beginning to tackle in their processes.

A Shifting Global Supply Chain Landscape (Why Now)

The ongoing change in pharmaceutical supply chains has undergone a period of change. While global buyers are increasingly exploring supplier diversification within their infrastructure, this shift has been driven by the requirements of the industry.

India is at the center of this evolution. The country supplies approximately 40 percent of generic medicines consumed in the United States and holds the largest number of FDA-approved manufacturing facilities outside America itself. For US healthcare buyers, distributors, and regulators, the reliability of Indian pharmaceutical supply chains is not an abstract concern; it is a daily operational reality.

Despite this, the broader ecosystems have been fragmented for some time, during which manufacturing, regulatory processes, and distribution have been handled by separate businesses, which often leads to slower production timelines.

Understanding the Platform Model in Pharma (What It Is)

Platform-based models in pharmaceutical supply chains center on the coordination between various aspects of infrastructure. By integrating manufacturing, regulatory, and distribution processes, platforms can streamline their processes through a unified process.

At DCAT Week 2026, the pharmaceutical sector’s most influential annual gathering held in New York, the industry recognized what HRV Pharma has built - The world’s first Virtual API Platform. The company owns no manufacturing facilities. Instead, it holds proprietary regulatory intellectual property in the US: Drug Master Files (DMFs). These DMFs govern how active pharmaceutical ingredients are approved for sale in regulated markets, alongside co-owned product approvals in the US. The company reports that manufacturing is executed through a pre-validated, curated network of 50+ FDA and EU-GMP certified partners across India. It is designed to serve as a single coordination point for buyers across more than 55 countries.

The Role of Data and AI in Operational Efficiency

Data and digital tools are now playing an important role in modern operations. Within platform-based models like HRV Pharma, these tools often support decision-making tactics that not only improve efficiency but also enhance visibility.

Within platforms like HRV Pharma, these tools support partner selection, compliance monitoring, and supply risk assessment across a network of 50+ certified manufacturers, tasks that would be operationally impossible to manage manually at scale. The goal is not to replace regulatory expertise, but to make it faster and more consistent across a large, distributed network.

Balancing Innovation with Transparency and Oversight

As new models continue to emerge, they will have to be evaluated within the framework of established regulatory concerns. In pharmaceutical industries, validation, documentation, and verification remain essential when it comes to trust and compliance.

Platform-based models are not exempt from these rules. Their effectiveness depends on the regulatory validation of products and processes, the verification of manufacturing partnerships, as well as clear documentation of claims and capabilities.

While supply chains are working toward more flexible and coordinated structures, there has been an increasing emphasis on strategy within the broader shift. Through a focus on integration, these platforms offer ways to navigate the complexity of manufacturing.

For American patients, healthcare buyers, and policymakers watching the resilience of drug supply chains, the emergence of platform-based models may be worth noting as a potential response to long-standing fragmentation in the system. The companies demonstrating this model can work with outcomes, not just intentions, may well define what pharmaceutical supply chains look like in the decade ahead.

The information provided in this article is for general informational and educational purposes only. It is not intended as legal, financial, medical, or professional advice. Readers should not rely solely on the content of this article and are encouraged to seek professional advice tailored to their specific circumstances. We disclaim any liability for any loss or damage arising directly or indirectly from the use of, or reliance on, the information presented.